This implementation guide was developed to support hospital leaders’ efforts to successfully implement the best obstetric hemorrhage practices and tools to create active quality improvement processes to drive successful implementation. The following information outlines the objectives of this quality improvement collaborative, the methods to support it, and the expectations of both FPQC and participants. Use this information to communicate this opportunity throughout your organization and network.  Click here to view or download...

The initial group of hospitals who will be chosen to participate will be institutions who demonstrate readiness, commitment, and capacity to be a leading hospital for quality service delivery related to hemorrhage. This survey will be used to determine the first hospitals to participate in implementing the collaborative initiative.

We are seeking a cadre of hospitals in various settings across the state, representing all sizes and levels. In order to be considered for this initiative, each hospital must commit to obtaining active participation from a hospital administrator and a physician and nurse who will serve as project champions. The Collaborative will offer materials, training and technical assistance to those hospitals chosen to participate in this phase at no charge to the hospital. The hospital commitment will be for a period of 18 to 24 months with implementation of core recommendations beginning in October 2013. The hospital will set local priorities and determine which tools to adopt or adapt from a toolkit to be provided.

View / download the questionnaire here.


Instructions for Prework
The pre-work literature provides background and research on current practices in the areas of Identification, Evaluation, Treatment and Discharge of the infant with NAS. Please review the General and Treatment information; everyone will be working in these areas together at the action-planning meeting. Each expert team member will need to also review the information related to the breakout session you have chosen to be a part of.

NAS General:  The following articles are from national Groups and organizations as well as background articles.

Neonatal Drug Withdrawal:  AAP’s statement on neonatal drug withdrawal.  This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives.

Opiate treatment for opiate withdrawal in newborn infants (Review):  Cochran review of current literature assessing effectiveness and safety of using opiates for withdrawal in infants.

Neonatal Abstinence Syndrome Clinical Practice Guidelines:  Practice guidelines created by the Provincial Council for Maternal Child Health in Ontario

Prenatal Substance Abuse Short- and Long-term Effects on the Exposed Fetus:  AAP Committee on Substance Abuse and Committee on Fetus and Newborn report on the most common drugs involved in prenatal exposure, addresses primary care pediatrician’s role in prenatal exposure includes prevention, identification of exposure, recognition of medical issues, protection of the infant and follow-up of the exposed infant.

Neonatal abstinence syndrome:  A review that discusses the complex nature of maternal and other factors that can affect the infant’s display of neonatal abstinence syndrome (NAS), clinical presentation and treatment of NAS, and the impact of recent findings on future directions for research.

NICU Nurses’ Lived Experience:  primary aim of this qualitative methods study was to describe the lived experiences of neonatal intensive care unit (NICU) nurses with ethical and morally challenging issues.

NAS Management Algorithm Treat or not to Treat:  Example algorithm for determining whether to treat the infant

NAS Management Algorithm Stabilization on Morphine:  Example algorithm for maintaining or increasing dose of morphine

NAS Management Algorithm Weaning:  Example algorithm for weaning morphine

NAS Management Algorithm Backsliding:  Example algorithm for infants that have difficulties with weaning

PQCNC NAS Swimlane:  High-level process map indicating the steps in the identification, evaluation, treatment, and discharge of a patient.  Pages 1-4 look at the individual process of each area.  Page 5 shows the entire process


NAS Identification: The following articles are related to methods for identification of exposure

Perinatal Effects of Combined Use of Heroin, Methadone, and Amphetamine during Pregnancy and Quantitative Measurement of Metabolites in Hair:  There has been very limited research on the clinical features of newborns exposed to combined use of heroin, methadone, and amphetamine in the uterus. This study describes a technique for the quantification of drug metabolites in neonatal hair samples

Opioid Detection in Maternal and Neonatal Hair and Meconium:  Characterization of an At-Risk Population and Implications to Fetal Toxicology:  Identification of maternal opioid abuse in pregnancy is often difficult to ascertain in the absence of a reliable self-report. This study aimed to characterize an at-risk neonatal population for opioid exposures as well as other drugs of abuse and alcohol 

Identification and Management of Neonatal Abstinence Syndrome:  This article focuses on drug abuse during pregnancy, the withdrawal symptoms it may cause in the infant, ways to recognize an infant experiencing neonatal abstinence syndrome, and available scoring tools and treatment options.

Identifying Infants at Risk for Neonatal Abstinence Syndrome:  The main objective of this study was to analyze the consistency in using a standardized newborn toxicology screening protocol to identify infants at risk of developing neonatal abstinence syndrome

Drugs of abuse testing in meconium: In spite of increased sample preparation time relative to blood and urine, the long metabolic history, coupled with the ease and wide window of collection of meconium make it the ideal matrix for determining fetal drug exposure.

Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse:  In cases of clinical suspicion and a negative neonatal urine test, both meconium and hair are effective biological markers of in utero illicit drug exposure. Meconium may be more sensitive, but neonatal hair is available for three months whereas meconium is available for only one or two days.

Neo Methods for Neonatal Drug Screening:  Article that describes perinatal and neonatal complications of maternal use of cocaine, alcohol, opiates, and barbiturates in pregnancy. Provides established cutoffs of conventional immunoassays of urine for common substances of abuse. List the advantages of using meconium testing for substances of abuse. Describes the role of fatty acid ethyl esters in detecting prenatal alcohol exposure.

Prenatal Substance Exposure:  Maternal Screening and Neonatal Identification and Management:  Article that describes physical and neurobehavioral problems of neonates who were exposed to maternal substances of abuse. Delineates the purpose of universal screening. Characterizes the areas of inquiry represented by the 4P’s Plus assessment. Describes the significant features of neonatal abstinence syndrome. Delineates supportive measures for management of infants exposed prenatally to substances of abuse

Effectiveness of a targeted screening program in identifying infants with positive urine toxicology screening results in a regular neonatal nursery:  Study that compared the effectiveness in identifying infants with positive results on urine screening for drugs of abuse of a universal screening program and a targeted screening program on the basis of clinical suspicion.

Identifying Infants at Risk for Neonatal Abstinence Syndrome:  Main objective of this study was to analyze the consistency in using a standardized newborn toxicology screening protocol to identify at risk of developing NAS

Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium:  Study with the objective of assessing the agreement of testing for exposure contrasting specimens of meconium vs umbilical cord tissue.  Umbilical cord tissue performs as well as meconium in assessing fetal drug exposure to amphetamines, opiates, cocaine, and cannabinoids. Results of studies using the cord may have a more rapid return to the clinician.


NAS Evaluation:  The following articles are related to methods to evaluate for NAS 

The Opioid Exposed Newborn:  Assessment and Pharmacologic Management:  Review from the NIH to provide health care professionals with current evidence and practical guidelines for optimal evaluation and pharmacologic management of opioid exposed newborns.

Finnegan neonatal abstinence scoring system:  normal values for the first 3 days and weeks 5-6 in non-addicted infants:  The purpose of this study was to assess the variability of the scores in newborns and infants not exposed to opiates during the first 3 days of life and during 3 consecutive days in weeks 5 or 6.

Establishment of Inter-observer Reliability Using the Finnegan Neonatal Abstinence Scoring Tool:  Presentation that discusses the importance of attaining reliability with clinical screening tools and helping to determine inter-observer reliability

Management of neonatal abstinence syndrome in neonatal intensive care units:  a national survey:  Aim of the study was to determine the monitoring and treatment of NAS in NICU’s following opiate or polydrug exposure in utero

Implementing Practice Guidelines and Education to Improve Care of Infants With Neonatal Abstinence Syndrome:  Purpose was to develop and implement a program for the management of NAS and the use of the Finnegan tool.


NAS Treatment:  The following articles are related to treatment of NAS 

Clonidine as an Adjunct Therapy to Opioids for Neonatal Abstinence Syndrome:  A Randomized Controlled Trial:  Objective of the study was to determine if oral clonidine would reduce the duration of opioid detoxification for neonatal abstinence syndrome.

ABM Clinical Protocol #21:  Guidelines for Breastfeeding and the Drug-Dependent Woman:  Purpose of this protocol is to provide evidence-based guidelines for the evaluation and management of the drug-dependent woman choosing to breastfeed

Methadone Maintenance and Breastfeeding in the Neonatal Period:  This study-evaluated concentrations of methadone in breast milk among breastfeeding women and concentrations of methadone in maternal and infant plasma in both groups.  Results contribute to the recommendation of breastfeeding for methadone-maintained women

Effects of Breast Milk on the Severity and Outcome of Neonatal Abstinence Syndrome Among Infants of Drug-Dependent Mothers:  The purpose of this research was to assess the effects of breast milk on the severity and outcome of neonatal abstinence syndrome.

Buprenorphine:  A Newer Drug for Treating Neonatal Abstinence Syndrome:  Article reviews current literature on Buprenorphine and use in NAS

Comparison of chlorpromazine versus morphine hydrochloride for treatment of neonatal abstinence syndrome:  Aim of study was to compare the duration of treatment for neonatal abstinence syndrome (NAS) using chlorpromazine versus morphine hydrochloride.  Conclusion: CP appears to shorten the duration of NAS compared with MH. Larger prospective randomized trials are needed to confirm our findings.

Use of clonidine in the prevention and management of neonatal abstinence syndrome:  Presentation of case series in which clonidine was used for the prevention and management of patients with NAS.  Data suggest that clonidine may be a reasonable alternative to more traditional agents used to prevent or treat NAS.

Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants:  The purpose of this study was to test the hypothesis that treatment of neonatal opiate withdrawal (NOW) in the term infant with diluted tincture of opium (DTO) and phenobarbital was superior to treatment with DTO alone.

Identification and Management of Neonatal Abstinence Syndrome:  This article focuses on drug abuse during pregnancy, the withdrawal symptoms it may cause in the infant, ways to recognize an infant experiencing neonatal abstinence syndrome, and available scoring tools and treatment options.

A Retrospective Study of Length of Hospital Stay in Infants Treated for Neonatal Abstinence Syndrome With Methadone Versus Oral Morphine Preparations:  Purpose of study:  Length of hospital stay (LOS) of infants treated for neonatal abstinence syndrome (NAS) with methadone was compared to LOS of those treated with an oral morphine preparation (OMP, neonatal morphine solution, or deodorized tincture of opium).

The Opioid Exposed Newborn:  Assessment and Pharmacologic Management:  Review from the NIH to provide health care professionals with current evidence and practical guidelines for optimal evaluation and pharmacologic management of opioid exposed newborns.

Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome:  Objective of study was To identify maternal and neonatal factors that impact response to methadone therapy for neonatal abstinence syndrome.

Neonatal Abstinence Syndrome:  Therapeutic Interventions:  This article provides an overview of the possible risks, benefits, and outcomes of pharmacologic and complementary therapies in the neonatal population, and illustrates the gaps in knowledge related to their use for neonatal withdrawal.

The Opioid Dependent Mother and Newborn Dyad:  Nonpharmacologic Care:  The purpose of this article is to review the contribution of maternal opioid dependency to the difficulties experienced by the mother-infant dyad and their treatment providers in the postnatal period, and the nonpharmacologic treatment of the infants with suggestions for practical measures with emphasis on the treatment of the mother and baby as an interactional dyad.

Update on the pharmacologic management of neonatal abstinence syndrome:  This review addresses risk factors and pathophysiology of NAS, summarizes parameters of common drugs used for the management of NAS, and reviews published literature of standard therapies as well as newer agents.

Differences in the profile of neonatal abstinence syndrome signs in methadone-versus buprenorphine-exposed neonates:  Aim was to compare the profile of signs of neonatal abstinence syndrome (NAS) in methadone- versus buprenorphine-exposed infants.

Management of neonatal abstinence syndrome:  a national survey and review of practice:  Aim was To ascertain the present management of neonatal abstinence syndrome (NAS) in neonatal units in the United Kingdom (UK) and Ireland

Rooming-in compared with standard care for newborns of mothers using methadone or heroin:  Objective was to evaluate the effect of rooming-in (rather than standard nursery care) on the incidence and severity of neonatal abstinence syndrome among opioid-exposed newborns and on the proportion of mothers who retain custody of their babies at hospital discharge.


NAS Discharge:  The following articles are related to discharge concerns for NAS patients

Hospital stay and short-term follow-up of children of drug-abusing mothers born in a urban community hospital:  Review of current NAS practices in regard to short term outcomes.  New ways to ensure better coordination of care should be developed.

Opioid Dependency in Pregnancy and Length of Stay for NAS:  Objective of the study was to examine opioid replacement therapy in pregnancy and effect on neonatal outcomes, including LOS for NAS.

Neonatal abstinence syndrome:  transitioning methadone-treated infants from an inpatient to an outpatient setting:  The objective of this study is to compare the safety and efficacy of a traditional inpatient only approach with a combined inpatient and outpatient methadone treatment program

A pilot study assessing the frequency and complexity of methadone tapers for opioid abstinence syndrome in children discharged to home:  The objective of this study was to determine the percentage of children discharged home on methadone tapers and to develop, assess, and implement an instrument for measuring the complexity of the methadone regimens.


ACOG Practice Bulletin Diagnosis and Management of Preeclampsia and Eclampsia:  This bulletin provides guidelines for the diagnosis and management of hypertensive disorders unique to pregnancy, as well as the various associated complications.  Note: No link as ACOG has specifically asked that this information NOT be shared.

Recommendations for Blood Pressure Measurement in Humans and Experimental Animals:  Accurate measurement of blood pressure is essential to classify individuals, to ascertain blood pressure–related risk, and to guide management.  This article provides recommendations from the American Heart Association on correct blood pressure monitoring.

Alternative magnesium sulphate regimens for women with preeclampsia and eclampsia:  Cochran review  to assess the comparative effects of alternative regimens for the administration of magnesium sulphate when used for the care of women with pre-eclampsia or eclampsia, or both.

Antihypertensive drug therapy for mild to moderate hypertension during pregnancy:  Cochran review to assess the effects of antihypertensive drug treatments for women with mild to moderate hypertension during pregnancy

ACOG Practice Bulletin - Chronic Hypertension in Pregnancy:  The purpose of this document is to review the effects of chronic hypertension on pregnancy, to clarify the terminology and criteria used to define and diagnose it during pregnancy, and to review the available evidence for management options. Note: No link as ACOG has specifically asked that this information NOT be shared.

Diagnosis and Management of Gestational Hypertension and Preeclampsia:  This article provides diagnosis criteria and classifications of hypertension in pregnancy and management strategies.

Magnesium sulfate prophylaxis in preeclampsia:  Lessons learned from recent trials:  Article that discusses recent trials using magnesium sulfate in preeclampsia

Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial:  a randomized placebo controlled trial:  The Magpie Trial (MAGnesium sulphate for Prevention of Eclampsia) was a large international trial designed to evaluate the effects of magnesium sulphate on women and their babies. The aim was to find out if, overall, women with pre-eclampsia or their children, or both, do better if they are given magnesium sulphate rather than placebo, regardless of whether treatment is started before or after delivery and irrespective of any previous anticonvulsant therapy

Evaluation and management of severe preeclampsia before 34 weeks’ gestation:  Objective was to review the risks and benefits of expectant management of severe preeclampsia remote from term, and to provide recommendations for expectant management, maternal and fetal evaluation, treatment, and indications for delivery.

Management of Late Preterm and Early-Term Pregnancies Complicated by Mild Gestational Hypertension/Pre-Eclampsia:  Provides summaries of studies and treatment recommendations

Magnesium Sulfate in Women With Mild Preeclampsia:  A Randomized Controlled Trial:  A randomized control trial with the objective to determine whether magnesium sulfate prevents disease progression in women with mild preeclampsia.

Management of hypertensive disorders during pregnancy:  summary of NICE guidance:  A summary of guidelines in the treatment of hypertension

Oral beta-blockers for mild to moderate hypertension during pregnancy:   Cochran review to assess whether oral beta-blockers are better than placebo, or no beta-blocker, and have advantages over other antihypertensives, for women with mild to moderate pregnancy hypertension.

How to manage hypertension in pregnancy effectively:  Article discusses management of hypertension and other aspects of care for the hypertensive pregnant patient

Prediction of adverse maternal outcomes in pre-eclampsia development and validation of the fullPIERS model:  The fullPIERS model identifi es women at increased risk of adverse outcomes up to 7 days before complications arise and can thereby modify direct patient care (eg, timing of delivery, place of care), improve the design of clinical trials, and inform biomedical investigations related to pre-eclampsia.

Instituting Surveillance Guidelines and Adverse Outcomes in Preeclampsia:  A study to assess the incidence of combined adverse maternal and perinatal outcomes in women with preeclampsia before and after introducing standardized assessment and surveillance.

WHO recommendations for Prevention and treatment of pre-eclampsia and eclampsia:  Recommendations from the World Health Organization on prevention and treatment of preeclampsia and eclampsia

Pregnancy Medical Home Program Care Pathway:  Management of women with hypertensive disorders of pregnancy.  This pathway provides definitions of the disorders to better standardize the language used with hypertension and details management of each stage of hypertension.

Improving Health Care Response to Preeclampsia: A California Quality Improvement Toolkit - The toolkit provides a series of articles on best practices for hypertensive disorders that range in topic from diagnostic challenges to appropriate implementation of accepted medical therapy and recognition of institutional limitations in providing care for these complex maternal patients. Of particular interest, the toolkit addresses the management of severe preeclampsia < 34 weeks, the importance of recognition and treatment of delayed postpartum preeclampsia/eclampsia in the emergency department and early postpartum follow-up upon discharge. In addition, the toolkit provides care guideline summaries (in checklist, flowchart and table chart formats)